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Summary
 
Here we provide evidence that the Ikaros family of DNA binding factors is critical for the ac-
tivity of hemopoietic stem cells (HSCs) in the mouse. Mice homozygous for an 
 
Ikaros 
 
null mu-
tation display a 
 
.
 
30-fold reduction in long-term repopulation units, whereas mice homozy-
gous for an 
 
Ikaros
 
 dominant negative mutation have no measurable activity. The defect in HSC
activity is also illustrated by the ability of wild-type marrow to repopulate unconditioned 
 
Ikaros
 
mutants. A progressive reduction in multipotent CFU-S
 
14
 
 (colony-forming unit-spleen) pro-
genitors and the earliest erythroid-restricted precursors (BFU-E [burst-forming unit-erythroid])
is also detected in the 
 
Ikaros
 
 mutant strains consistent with the reduction in HSCs. Nonetheless,
the more mature clonogenic erythroid and myeloid precursors are less affected, indicating either
the action of a compensatory mechanism to provide more progeny or a negative role of 
 
Ikaros
 
at later stages of erythromyeloid differentiation. In 
 
Ikaros
 
 mutant mice, a decrease in expression
of the tyrosine kinase receptors flk-2 and c-kit is observed in the lineage-depleted c-kit
 
1
 
Sca-1
 
1
 
population that is normally enriched for HSCs and may in part contribute to the early hemo-
poietic phenotypes manifested in the absence of 
 
Ikaros
 
.
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T
 
he hemopoietic system is derived from the mesodermal
germ layer early in embryogenesis (1–3). Hemopoietic
commitment of the elusive hemangioblast, a mesodermally
derived progenitor that gives rise to vascular endothelium
and hemopoietic cells (4), occurs over a narrow window of
time during embryogenesis. Once established, the hemo-
poietic system supplies the organism with at least 10 differ-
ent lineages in a highly regulated manner. As the half-life of
mature hemopoietic cells varies from several hours to years,
a continuous production of end-stage cells from hemopoi-
etic stem cells (HSCs)
 
1
 
 is required throughout the life span
of the organism. Accordingly, HSCs must be capable of
self-renewal to maintain the HSC pool and its more mature
progeny. Differentiation from the HSC proceeds through a
series of progressive restrictions that give rise to multipo-
tent progenitors with short-term repopulating ability, lin-
eage-restricted precursors, and, finally, terminally differen-
tiated cells (5). To increase the number of mature progeny,
proliferative expansions take place along various stages in
these pathways. The molecular control of hemopoiesis has
been the focus of intense study. The role of membrane re-
ceptors, underlying signaling pathways, and potential nuclear
effectors has been studied in both vertebrates and inverte-
brates (6–9).
Ikaros is a hemopoietic-specific member of a family of
zinc finger transcription factors that is essential for specifica-
 
tion in lymphoid lineages (10, 11). 
 
Ikaros
 
 generates by means
of alternate splicing a number of protein isoforms (12, 13)
that share a common COOH-terminal zinc finger domain
that mediates interactions with self and other family mem-
 
bers (14, 15). A subset of the 
 
Ikaros
 
 isoforms (Ik-1, Ik-2, Ik-3,
Ik-4) has a second zinc finger domain located at the NH
 
2
 
-
terminal half that mediates sequence-specific DNA interac-
 
tions (12). The remaining 
 
Ikaros
 
 isoforms, Ik-5, Ik-6, and Ik-7,
do not have a DNA-binding domain yet can negatively
regulate the activity of the DNA-binding Ikaros proteins
(12, 14). Although functionally distinct, both Ikaros zinc
finger domains are essential for high-affinity interactions
with DNA and are indispensable for transcriptional activ-
 
ity (reference 14 and Koipally,
 
 
 
J., and K. Georgopoulos,
unpublished results). The relative expression levels of
Ikaros splicing variants do not change significantly during
development; the DNA-binding isoforms Ik-1, Ik-2, and
 
1
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 AGM, aorta-gonad-mesonephros regions;
BM, bone marrow; CFC, colony-forming cell; DN, dominant negative;
G, granulocytes; HSCs, hemopoietic stem cells; LTR, long-term repopu-
lation; M, macrophages; RT, reverse transcriptase; YS, yolk sac. 
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Ik-4 are the predominant species in the hemopoietic popu-
lations analyzed thus far (12, 15).
Two distinct deletions have been targeted independently
in the 
 
Ikaros
 
 locus in mice (10, 11). Mice homozygous for
a deletion in the last translated exon that encodes the
COOH-terminal half of the Ikaros proteins are null for any
Ikaros protein (11). Ikaros null mice lack both fetal and
adult mature B cells as well as the earliest defined B lineage
precursors. Fetally derived T cells and their precursors are
also absent; however, postnatally, a severely reduced num-
ber (10–30-fold reduction) of T cell precursors appears in
the thymus (16). These T cell precursors undergo abnormal
differentiation along the CD4 
 
a
 
/
 
b
 
 T cell pathway, are un-
able to differentiate along the NK lineage, and produce
severely reduced numbers of 
 
g
 
/
 
d
 
 T cells and thymic dendri-
tic APCs (11, 17). A distinct 
 
Ikaros
 
 mutation that deletes
part of the NH
 
2
 
-terminal zinc finger domain abolishes the
DNA binding capability of Ikaros proteins but leaves the
COOH-terminal zinc finger interaction domain intact. Pro-
teins are stably produced by this Ikaros mutant allele, which
can interfere with the activity of the DNA-binding Ikaros
isoforms and with other Ikaros family members (14, 15, 18).
Consistent with these in vitro observations, mice homozy-
gous for the 
 
Ikaros
 
 dominant negative (DN) mutation dis-
play more severe lymphoid defects relative to 
 
Ikaros
 
 null
mice. 
 
Ikaros
 
 DN
 
2
 
/
 
2
 
 mice lack all cells of lymphoid origin,
including NK cells and thymic and splenic APCs (10, 17).
In addition, mice heterozygous for the 
 
Ikaros
 
 DN mutation
develop T cell leukemias and lymphomas with 100% pene-
trance within the first 4 mo of their lives (19). The more
severe effects on development and homeostasis of the lym-
phoid lineage caused by the 
 
Ikaros
 
 DN mutation suggest
that Ikaros DN proteins interfere with the activity of other
family members during lymphopoiesis. One of the 
 
Ikaros
 
homologues, 
 
Aiolos
 
, is expressed in lymphoid precursors
and mature lymphocytes and interacts both physically and
functionally with Ikaros (reference 15 and Cortez,
 
 
 
M., and
K. Georgopoulos, unpublished data). Two additional fam-
ily members, 
 
Helios
 
 and 
 
Dedalos
 
, also form complexes with
Ikaros and colocalize within higher order nuclear structures
(18, 20, and Morgan, B., manuscript in preparation). Both
 
Helios
 
 and 
 
Dedalos
 
 are expressed in populations enriched for
HSCs and in early thymic T cell precursors (reference 18
and Morgan, B., manuscript in preparation). We have re-
cently identified Ikaros and family members in two distinct
higher order chromatin remodeling complexes having nu-
clear compartmentalization and gene targeting that relies
on the DNA binding activity shared by Ikaros and its fam-
ily members (21). Thus, the more severe phenotypes mani-
fested in 
 
Ikaros
 
 DN mutants may be due to interference
with the Aiolos, Helios, and Dedalos protein activity and
inappropriate targeting of the Ikaros-associated chromatin
remodeling complexes.
In this study, we delineate the effects on HSC activity
manifested by the 
 
Ikaros
 
 null and DN mutations. The ef-
fects of the 
 
Ikaros
 
 mutations are apparent in long-term re-
population (LTR) activity, which is reduced by 20–40-fold
in 
 
Ikaros
 
 null mutants and is undetectable in 
 
Ikaros
 
 DN ho-
 
mozygotes. The more committed multipotent CFU-S
 
14
 
(colony-forming unit-spleen) progenitors and the earliest
erythroid-restricted precursors (BFU-E [burst-forming
unit-erythroid]) are also reduced in 
 
Ikaros
 
 mutant mice to
an extent that correlates with the reduction in HSC activ-
ity. Nevertheless, the more mature clonogenic precursors,
including CFU-E, are less affected. 
 
Ikaros
 
 null HSCs and
DN
 
2
 
/
 
2
 
 hemopoietic progenitors lack expression of the ty-
rosine kinase receptor flk-2 at the mRNA level and express
progressively reduced levels of the tyrosine kinase receptor
c-kit at the cell surface.
 
Materials and Methods
 
Mice. Ikaros 
 
null and DN mutant mice as well as wild-type
control littermates on a mixed C57BL/6J 
 
3
 
 129SV background
were bred and maintained under sterile conditions in a pathogen-
free animal facility at Massachusetts General Hospital. Due to the
high morbidity of the 
 
Ikaros 
 
DN mutant mice, all animals were
kept on oral antibiotics. Mice used for the different studies were
between 2 and 5 wk old. The genotypes of mice were determined
by PCR analysis of the 
 
Ikaros 
 
locus with primers and conditions
described previously (10). C57BL/6J–Ly5a-Pep
 
3b
 
–congenic mice
used as transplant recipients or donors were obtained from The
Jackson Laboratory and bred in the animal facility.
 
Hemopoietic Tissue Preparation.
 
Bone marrow (BM) was pre-
pared by crushing femora and tibiae with a mortar and pestle and
then passing the suspension through a 70-
 
m
 
m cell strainer to re-
move bone debris. Spleen cell suspensions and day 14 fetal liver
cells were obtained by disrupting the tissue in PBS (plus
 
 
 
5% dial-
ysed FBS) and passing it through a 70-
 
m
 
m cell strainer. The aorta-
gonad-mesonephros regions (AGM) and yolk sacs (YS) from 11 d
postcoitum embryos were prepared as described previously (22).
In brief, the AGM and YS were dissected in PBS/5% FCS and
digested for 1 h at 37
 
8
 
C in 0.125% collagenase (Sigma Chemical
Co.). Viable cell counts were based on trypan blue exclusion.
 
mAbs.
 
The mAbs used for immunofluorescent labeling and
the fluorochromes employed are specified elsewhere (17). In brief,
three-color flow cytometry was performed using anti-Ly5b (AL1-
4A2) to identify donor-derived cells and antibodies against B220
(RA3-6B2), CD4 (RM4-5), CD8 (53-6.7), TCR-
 
a
 
/
 
b
 
 (H57-597),
Mac-1 (M1/70), Gr-1 (RB6-8C5), and TER-119. All antibodies
were purchased from PharMingen.
 
In Vitro Colony-forming Cell Assay.
 
Marrow and spleen cells were
harvested from neonate and 2–5-wk-old mice. Single-cell sus-
pensions from each tissue were prepared in PBS (plus 5% dialysed
FBS), counted, and cultured in IMDM containing 1.2% methyl
cellulose, 15% FBS, 0.5% BSA fraction V, transferrin, insulin, lipids,
 
a
 
-thioglycerol, 15 U/ml IL-3, 2 IU/ml erythropoietin, and 50
ng/ml kit ligand. Colonies were scored after 2–3 d for CFU-E
and after 7–10 d for all other colony types. Erythroid colonies
containing at least two other lineages were attributed to colony-
forming cell (CFC)-multi. Pure erythroid colonies on day 7–8
were attributed to BFU-E, and colonies containing at least 500
granulocytes (G) and/or macrophages (M) were attributed to
CFC-G/M. Purified murine kit ligand was provided by Genetics
Institute.
 
Spleen Colony-forming Assay (CFU-S
 
14
 
).
 
The CFU-S
 
14
 
 content
in the BM and spleens of 
 
Ikaros 
 
mutant and wild-type littermates
2–5 wk after birth was determined by injection of 5 
 
3
 
 10
 
4
 
 nucle-
ated BM cells or 2.5 
 
3
 
 10
 
5
 
 spleen cells into the lateral tail vein of
lethally irradiated (9.5 Gy; 
 
137
 
Cs single dose) wild-type recipient 
1203
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mice. Mice were killed 14 d after the injection, and their spleens
were fixed in Bouin’s solution for macroscopic examination and
weighing. Absolute numbers of CFU-S
 
14
 
 per organ were calcu-
lated based on the frequency measurement and the cellularity of
the spleen and the BM, assuming that one femur and one tibia
represent 10 and 5%, respectively, of total BM. To determine the
lineage composition of spleen colonies, single colonies were dis-
sected before fixation, erythrocytes were lysed in 0.4 M ammo-
nium chloride buffer, and cells were stained with a subset of anti-
bodies described previously and subjected to FACS™ analysis.
For PCR genotyping, colonies were lysed in DNA lysis buffer,
and DNA was prepared as previously described (10). Irradiated
mice injected with PBS alone were included as controls in all ex-
periments.
 
Radioprotection and Competitive Repopulation Assays.
 
Congenic
C57BL/6J–Ly5a-Pep
 
3b
 
 
mice were irradiated with a single lethal
dose of 9.5 Gy from a 
 
137
 
Cs radiation source (gamma irradiator;
J.L. Shepherd) at 0.95 Gy/min. Cell suspensions containing 10
 
5
 
wild-type or 6 
 
3
 
 10
 
6
 
 mutant BM cells from 2–5-wk-old mice in
a final volume of 200 
 
m
 
l PBS were injected intravenously into the
lateral tail vein. Recipient mice were maintained on 1.1 g/liter
neomycin sulfate (Sigma Chemical Co.) and 10
 
6
 
 U/liter poly-
myxin B sulfate (Sigma Chemical Co.) in their drinking water for
the duration of the assay. Mice were monitored for survival daily
for 35 d. For the competitive assays, lethally irradiated Ly5a mice
(9.5 Gy of gamma irradiation) were injected with
 
 
 
a fixed amount
of
 
 
 
10
 
5
 
 Ly5a autologous BM cells along with 10
 
5
 
–10
 
7
 
 
 
Ikaros 
 
mu-
tant or wild-type BM cells (Ly5b). Donor-derived (Ly5b) hemo-
poietic contribution was measured from the peripheral blood at
different time points starting on day 19 after transplant and from
both peripheral blood and hemopoietic organs at the time mice
were killed.
 
HSC Enrichment.
 
BM cells were collected from femora and
tibiae of 2–5-wk-old mice. Cells were layered at 2.5 
 
3
 
 10
 
7
 
 cells/ml
over 3 ml of sodium metrizoate (Nycodenz; Accurate Scientific) so-
lution (1.077 g/ml) and centrifuged at 1,000 
 
g
 
 for 20 min. Low
density cells were harvested and incubated with mAbs to CD4,
CD8, B220, Mac-1, Gr-1, and TER-119 (all antibodies are rat
IgG), followed by goat anti–rat IgG coupled to magnetic beads
(Miltenyi Biotec). Lin
 
1
 
 cells were depleted by attachment to a mag-
netic column according to manufacturer’s instructions (MACS™;
Miltenyi Biotec). For cell sorting and analysis, the lineage-depleted
 
(lin
 
2
 
) population was incubated again with the lineage antibodies
followed by goat anti–rat IgG conjugated to allophycocyanin
(Caltag Labs.), normal rat IgG (Caltag Labs.), and antibodies to
c-kit (PE conjugate; PharMingen) and Sca-1 (fluorescein conju-
gate; PharMingen). Cells were then analyzed in a dual laser cell
sorter (FACScan™; Becton Dickinson). Cells within the blast
forward and side light scatter gate that were negative for the lin-
eage markers were gated electronically and analyzed for or sorted
according to expression of c-kit and Sca-1.
 
Reverse Transcriptase–PCR.
 
RNA purification, first-strand cDNA
synthesis, and PCR amplification were performed as described
previously (15). PCR primers used were as follows: HPRT F, CAC
AGG ACT AGA ACA CCT GC; HPRT R, GCT GGT GAA
AAG GAC CTC T; FLK1 F, AGA ACA CCA AAA GAG AGG
AAC G; FLK1 R, GCA CAC AGG CAG AAA CCA GTA G;
FLK2 F, GGA GGA GGG CAG CTA CTT TGA G; FLK2 R,
CTG TTA GCC TTT TTA TTC CAA ACT C; GATA1 F, CAT
TGG CCC CTT GTG AGG CCA GAG A; GATA1 R, CGG
AGA TAA AGT TCG AGG TAG TCC A; GATA2 F, ACA CAC
CAC CCG ATA CCC ACC TAT; GATA2 R, CCT AGC CCA
TGG CAG TCA CCA TGC; GATA3 F, ACG TCT CAC TCT
CGA GGC AGC ATG; GATA3 R, GAA GTC CTC CAG CGC
GTC ATG CAC; SCL F, GTC CTC ACA CCA AAG TAG TG;
SCL R, GGC ACC TCA AAG CTT GAC TCT CCA; GMCSF
F, GAG GTC ACA AGG TCA AGG TG; GMCSF R, GAT TGA
CAG TGG CAG GCT TC; PU1 F, GAG TTT GAG AAC TTC
CCT GAG; PU1 R, TGG TAG GTC ATC TTC TTG CGG.
 
Results
 
Extramedullary Hemopoiesis and Development of Anemia in
Ikaros Mutant Mice.
 
In 
 
Ikaros
 
 null and DN
 
2
 
/
 
2 mice, the BM
cellularity is decreased to 37 and 18% of wild-type levels
(Fig. 1 A), exceeding the reduction expected from the lack
of B lymphocytes and their precursors. In normal adult mice,
the spleen is the secondary hemopoietic organ, with 80–90%
of its population comprised of B and T lymphocytes and
10–20% of the cells being of erythromyeloid origin. In
Ikaros null mice, the cellularity in the spleen is reduced to
only 62% of wild-type levels, a much smaller reduction
Figure 1. BM hypoplasia, extramedullary
hemopoiesis, and progressive anemia in
Ikaros mutant mice. (A) BM and spleen cel-
lularity of Ikaros mutant relative to wild-
type mice. BM cellularity is calculated from
the cell content of the two hind limbs (30%
of total BM). Both BM and spleen cell sus-
pensions were counted after erythrocyte ly-
sis. The cellularity of the wild-type organs is
set to 1.0, and mutant values are indicated as
a proportion thereof. Numbers of animals
included in the analysis were: wild-type, n 5
20; Ikaros null, n 5 16; and Ikaros DN2/2,
n 5 18. (B) Hematocrits in wild-type and
Ikaros DN mutant mice are shown as a func-
tion of age. Wild-type mice and mutant lit-
termates were bled at the indicated ages and
their hematocrits read in a Readacrit centri-
fuge. Ikaros DN2/2 mutant mice (d) ini-
tially had hematocrits similar to those of age-matched control littermates (u), but their hematocrits dropped to ,50% of wild type by 6 wk of age. Num-
ber of mice bled is as follows: 1/1, 2–3 wk old, n 5 4; 1/1, 3–4 wk old, n 5 9; 1/1, 4–5 wk old, n 5 4; 1/1, 5–6 wk old, n 5 5; 1/1, over 6 wk old,
n 5 4; 2/2, 2–3 wk old, n 5 7; 2/2, 3–4 wk old, n 5 9; 2/2, 4–5 wk old, n 5 5; 2/2, 5–6 wk old, n 5 4; and 2/2, over 6 wk old, n 5 4.1204 Regulation of HSCs by Ikaros
than that expected given the lack of B cells and impaired T
cell development (11, 17). Ikaros DN2/2 mice, which lack
both B and T lymphocytes, also show a reduction to only 57%
of the cellularity of the wild-type organ (Fig. 1 A). Taken
together, these results reveal a significant increase in myelo-
erythroid cells in the spleens of Ikaros mutants. Such dispro-
portionate changes in hemopoietic populations between BM
and spleen are indicative of extramedullary hemopoiesis.
We have previously shown (11) that Ikaros null mice have
normal hematocrits throughout their life spans. Ikaros DN2/2
mice, however, display a drop in hematocrit with age (Fig.
1 B). The hematocrits of 2–3-wk-old Ikaros DN2/2 mice
are similar to those of wild-type littermates but soon after
drop and by 6 wk of age reach a value of ,50% of wild-
type levels. During this period, Ikaros DN2/2 mice also de-
velop extensive infections from opportunistic microorgan-
isms and die (10). Therefore, the cause of death in these
mice cannot be unequivocally ascribed to the lack of an
immune system or to hemopoietic failure but rather may
be due to both. Thus, in addition to lymphoid defects,
Ikaros deficiency has other effects on hemopoiesis.
Radioprotection Capabilities of Ikaros Null and DN2/2 BM.
Mice exposed to high doses of whole body irradiation die
within 9–18 d from hemopoietic failure unless they are
transplanted with hemopoietic precursors and progenitors
that provide radioprotection and short-term reconstitution.
The radioprotective quality of Ikaros null and DN2/2 BM
was assayed in strains of mice congenic for the panleuko-
cyte marker Ly5. Both Ikaros null and DN2/2 donor mice
expressed the Ly5b variant, whereas the transplant recipi-
ents expressed the Ly5a allele.
Ikaros null and wild type BM cells, when given at a dose
of 105 cells, radioprotected 100% of the lethally irradiated
(900 rads) recipients for at least 30 d after transplant (Fig.
2 A). Animals receiving 106 Ikaros null BM had almost
100% donor contribution to the myeloid (Mac-11) lineage
7 mo after transplant (Fig. 2 B, left). Ikaros DN2/2 BM cells
provided at doses of 1–6 3 106 were capable of only short-
term radioprotection at first (Fig. 2 A), with a steady de-
crease in donor contribution observed between 3.5 and
5 wk after transplant (Fig. 2 B, right). The hematocrits of
Ikaros DN2/2 BM recipients also decreased during this time
period. 3 wk after transplant, hematocrits of Ikaros DN2/2
BM recipients were ,50% of wild-type BM recipients, and
by day 35 they were down to one-third of wild-type values
(Fig. 2 C). All recipients of Ikaros DN2/2 BM died by day
35 after transplant from severe anemia.
Given the extramedullary hemopoiesis manifested in
the spleens of Ikaros DN2/2 mice, we examined whether
hemopoietic progenitors developed in this secondary he-
mopoietic site. Splenocytes from these mutants were un-
able to radioprotect even when provided at a dose of 1.2 3
107 cells (data not shown). This observation suggests that
there is no shift in the production or expansion of hemo-
poietic progenitors from the BM to the spleen and that ex-
tramedullary hemopoiesis at this site is due to the differen-
tiation of more committed and short-lived erythromyeloid
precursors.
Figure 2. Short-term radioprotection and repopulation
ability is unaffected by the Ikaros null mutation but
severely compromised by the Ikaros DN mutation. (A)
Short-term radioprotective ability of wild-type and Ikaros
mutant BM. Ly5a congenic mice were lethally irradiated
(9.5 Gy) and injected with 105 wild-type BM (j), 105
Ikaros null2/2 BM (u), 106 Ikaros DN2/2 BM (m), or
PBS alone (s). The numbers of mice injected per donor
group are given in the legend, and their age was 3–4 wk.
(B) Donor contribution in the myeloid lineage after
transplant with wild-type and Ikaros mutant BM. Ly5a
congenic mice were lethally irradiated and injected with
106 wild-type BM (gray bars), 106 Ikaros null BM (left
panel, hatched bars), or 6 3 106 Ikaros DN2/2 BM (right
panel, hatched bars). At the indicated time points after
transplant, recipients were bled and assayed for donor contribution to the myeloid (Mac-11) lineage by FACS™ analysis. A pool of four wild-type or
mutant mice was used as a donor population. The experiment was repeated twice, and data shown are the analysis of one representative mouse out of eight
recipients. (C) Development of lethal anemia in recipients of Ikaros DN2/2 BM. 5 3 106 Ikaros DN2/2 (d) or wild-type (h) BM cells were transplanted
into lethally irradiated recipients, and recipient hematocrits were monitored over 5 wk. Recipients of Ikaros DN2/2 BM (d) eventually died of anemia
5 wk after transplant. Numbers of mice bled were as follows: 1/1 recipients, n 5 12; and Ikaros DN2/2 recipients, n 5 28. Donors were 2–4 wk old.1205 Nichogiannopoulou et al.
Competitive Repopulating Units Are Reduced among Ikaros
Mutant Hemopoietic Cells. The LTR potential of Ikaros null
and DN2/2 BM was analyzed in a competitive repopula-
tion assay (23, 24). Ikaros mutant Ly5b BM cells were in-
jected into lethally irradiated Ly5a recipients along with a
constant competitor dose of 105 Ly5a marrow. When Ikaros
null BM (105) was transplanted with an equal amount of
wild-type competitor marrow, it failed to contribute to
myeloid (Mac-11) cells in the BM or the periphery of re-
cipients (Fig. 3 A, top right panel). In sharp contrast, wild-
type BM contributed to 44% of the BM myeloid (Mac-11)
populations (Fig. 3 A, top left panel). Ikaros null BM in-
jected in 10-fold excess (106) over wild-type competitor
gave 17% contribution to the myeloid (Mac-11) lineage in
the BM (Fig. 3 A, center panels). No significant contribu-
tion to the T cell lineage was observed in the thymus or the
spleen (data not shown). In comparison, wild-type BM
coinjected at a similar dose contributed to .99% of the
myeloid (Fig. 3 A, center panels) and lymphoid (data not
shown) populations in the BM and periphery. When 7.5 3
106 Ikaros null BM cells were injected alongside 105 com-
petitor BM cells, donor-derived contribution to the my-
eloid lineage increased to 75.3% (Fig. 3 A, bottom panels).
This analysis indicates that there is a 30–40-fold decrease in
LTR activity in the Ikaros null BM.
In a previous study (17), we reported short-term my-
eloid lineage contribution by Ikaros DN2/2 BM when in-
jected at a ratio of 100:1 over competitor BM. At this ratio,
Ikaros DN2/2 BM contributed to 52% of myeloid (Mac-11)
cells by 19 d after transplant, but by day 27, this contribu-
tion declined to 6% and by day 48 to 3% (Fig. 3 B). No
donor-derived myeloid contribution was detected 120 and
260 d after transplant (Fig. 3 B). PCR analysis of DNA pre-
pared from the blood, spleens, and BM of recipients also
failed to detect donor-derived cells, confirming the lack of
LTR activity in Ikaros DN2/2 BM (data not shown).
Thus, in the absence of Ikaros, LTR activity as estimated
in competitive repopulation assays is reduced by 30–40-fold.
However, a .100-fold reduction in LTR activity is observed
in mice homozygous for the DN Ikaros mutation.
BM Engraftment into Unconditioned Ikaros Mutant Recipients.
Lethal irradiation of normal murine recipients before BM
Figure 3. A progressive reduction in competitive
repopulation units from Ikaros null to Ikaros DN2/2
hemopoietic populations. (A) Competitive repopu-
lation assay with wild-type and Ikaros null mutant
BM. Lethally irradiated Ly5a mice were coinjected
with a mixture of test (wild-type [1/1] or Ikaros
null [Ik2/2]) Ly5b BM and a constant dose of 105
cells of competitor Ly5a BM at the indicated ratios.
At various times (3–12 mo) after transplant, recipi-
ent mice were killed and analyzed for the hemopoi-
etic contribution to marrow Mac-11 cells from test
and competitor populations by FACS™ analysis.
One representative out of four recipient mice killed
is shown. Donors were 4 wk old. (B) Lack of com-
petitive LTR activity in Ikaros DN2/2 BM. 5 3 106
Ikaros DN2/2 Ly5b BM cells were transplanted
along with 5 3 104 competitor Ly5a BM cells into
lethally irradiated Ly5a recipients. At the indicated
time points after transplant, recipient mice were
bled and contribution to the Mac-1 lineage from
each injected population was determined by
FACS™ analysis. The average of six recipients per
group is shown for each time point. Donors were
2–3 wk old.1206 Regulation of HSCs by Ikaros
transplant is required to ensure engraftment and detection
of donor-derived hemopoietic cells. However, if the he-
mopoietic system of the recipient is already compromised,
then donor-derived hemopoiesis is detectable even in the
absence of prior conditioning of the recipient. This phenom-
enon has been observed with c-kit receptor (W) mutant mice
(25). Given the depletion in hemopoietic progenitors result-
ing from the null and DN Ikaros mutations, we attempted to
repopulate unconditioned Ikaros mutants with wild-type BM.
A transplant of 106 wild-type Ly5a BM cells into uncon-
ditioned Ikaros null mice completely repopulated the B cell
lineage, consistent with the total lack of B cells and their
precursors in Ikaros mutants (Fig. 4 A, Ly5b2/B2201 cells).
Donor repopulation of T cells and some myelocytes was
also observed, albeit at low levels, possibly due to competition
with endogenous precursor populations (Fig. 4 A, Ly5b2/
TCR-a/b1 and Ly5b2/Mac-11/Gr-11).
Ikaros DN homozygous mutants and heterozygous litter-
mates were injected with 106 wild-type Ly5a BM cells at
12 d of age and subsequently analyzed at 4, 12, and 22 wk
after transplant. No detectable donor contribution in any
hemopoietic lineages was observed after transplant of wild-
type Ly5a BM into unconditioned Ly5b Ikaros DN hetero-
zygotes (Fig. 4 B, top panels, Ly5a1/lin1 cells). In striking
contrast, complete donor repopulation of B and T lympho-
cytes and myeloid cells was observed in unconditioned Ikaros
DN2/2 mice receiving 106 wild-type BM cells (Fig. 4 B,
bottom panels, Ly5a1/B2201, Ly5a1/TCR-a/b1, and
Ly5a1/Mac-11/Gr-1), which persisted for the full duration
of the experiment. To detect potential hemopoietic contri-
bution by endogenous Ikaros DN2/2 mutant cells at levels
that may fall below the detection limit of FACS™, PCR
analysis of DNA prepared from various hemopoietic tissues
was employed (Fig. 4 C). Given a PCR DNA detection
limit of 1:1,000 mutant/wild-type DNA (Fig. 4 C), we
conclude that host-derived hemopoietic cells were at least
1,000-fold less frequent in unconditioned Ikaros DN2/2 re-
cipients after transplant of wild-type BM.
Thus, the hemopoietic system of Ikaros null and DN2/2
mice is readily repopulated by wild-type HSCs without the
need for prior myeloablative conditioning. This repopula-
tion of unconditioned Ikaros mutant mice by wild-type
HSCs reflects a severe depletion in the endogenous pool.
Reduction in CFU-S14 in Ikaros Mutant Mice. The more
Figure 4. Hemopoietic lineage
repopulation in unconditioned Ikaros
mutant mice points to a severe de-
pletion in hemopoietic progenitors.
(A) 106 wild-type Ly5a BM cells
were injected into 3-wk-old Ly5b
Ikaros null mice without prior con-
ditioning. At different time points
(3–6 mo) after transplant, recipient
mice were killed and analyzed for
Ly5a contribution by FACS™ anal-
ysis. (B) 106 wild-type Ly5a BM cells
were injected intravenously into
12-d-old Ikaros DN1/2 or DN2/2
Ly5b recipients without prior condi-
tioning. At different time points after
transplant, recipient mice were
killed and analyzed for donor Ly5a
contribution by FACS™ analysis.
Analysis of representative recipients
5.5 mo after transplant is shown.
Top panels correspond to Ikaros
DN1/2 recipients, and bottom pan-
els correspond to Ikaros DN2/2 re-
cipients. (C) PCR analysis of the
hemopoietic organs of two indepen-
dent  Ikaros DN2/2 recipients of
wild-type BM. Total DNA was ex-
tracted from the hemopoietic organs
of wild-type control mice and Ikaros
DN2/2 mutant mice that were
transplanted with wild-type BM
without prior irradiation. No Ikaros
DN mutant DNA (upper band) is
detectable in DN2/2 recipients, in-
dicating lack of recipient contribu-
tion in any hemopoietic lineage.
The DNA titration (lanes 10–13) in-
dicates that the larger mutant band
can still be detected in a 1:1,000 di-
lution into the smaller, and thus more
readily amplifiable, wild-type band.1207 Nichogiannopoulou et al.
committed myeloid precursor content of Ikaros mutant
mice was investigated in a spleen colony-forming assay
(CFU-S14) (26). CFU-S14 levels in Ikaros null and DN2/2
BM were reduced 9.2- and 81-fold relative to wild type
(Fig. 5 A). Splenic CFU-S14 was also reduced by three- and
fivefold in Ikaros null and DN2/2 mice relative to wild type
(Fig. 5 A). The combined limb BM and splenic CFU-S14
contents of Ikaros null and DN2/2 mice were reduced 7.7-
and 34-fold relative to wild type. Although these data as-
sume similar spleen seeding efficiencies by wild-type and
Ikaros mutant CFU-S, we have not tested this hypothesis.
Qualitative effects of the Ikaros mutations on the size and
lineage composition of day 14 spleen colonies were also
observed. First, spleen colonies derived from Ikaros mutant
cells were smaller than those derived from wild-type popu-
lations (Fig. 5 A, bottom panels, arrows). Second, Ikaros
mutant colonies contained 20–40% of nucleated erythroid
(TER-1191) cells, whereas wild-type colonies consisted
mainly (76–91%) of more mature erythroid cells (data not
shown). The donor origin of the CFU-S14 colonies was
confirmed by PCR (data not shown). Interestingly, a small
number of endogenous colonies was detected in recipients
of Ikaros mutant BM and spleen but not in recipients of
wild-type populations or in PBS controls. A possible facili-
tating effect is suggested, perhaps in the form of growth
factors produced by the Ikaros mutant cells that promote
expansion and differentiation of endogenous progenitors.
The CFU-S14 content of day 10 YS and AGM and day
14 fetal livers of Ikaros DN2/2 mutant and wild-type em-
bryos was also measured. The CFU-S14 content in these late
embryonic and early fetal sites of hemopoiesis was drasti-
cally reduced in Ikaros DN2/2 embryos compared with
wild type (Fig. 5 C). Thus, the lack of Ikaros, coupled with
interference toward the activity of other family members,
affects the production of both fetal and adult hemopoietic
progenitors.
Effects of the Ikaros Mutations on In Vitro Clonogenic Precursors.
BM and splenic hemopoietic populations were analyzed for
their content of myeloid-restricted in vitro CFCs. The
absolute number of precursors giving rise to multilineage
colonies (CFC-multi) and G- and/or M-restricted colonies
(CFC-G/M) in Ikaros null BM was within the range of
Figure 5. Reduction in hemopoi-
etic progenitors (CFU-S14) caused by
the  Ikaros mutations. (A) Absolute
number of CFU-S14 in the two hind
limbs (left) and spleens (right) of
wild-type and Ikaros mutant mice.
Numbers do not include seeding ef-
ficiency conversions. Each square
represents the average of four recipi-
ents of either 5 3 104 BM or 2.5 3
105 spleen cells from one donor
mouse. The number of donor mice
is as follows: 1/1 BM, n 5 12; 1/1
spleen, n 5 12; DN BM, n 5 14;
DN spleen, n 5 14; null 2/2 BM,
n 5 10; and null 2/2 spleen, n 5
10. Donors were 2–4 wk old. Spleen
colonies generated upon injection of
wild-type and Ikaros mutant BM and
spleen are shown in the bottom pan-
els. (B) CFU-S14 content of day 10
YS (Yolk Sac-D10), day 10 AGM
(AGM-D10), and day 14 fetal liver
(Fetal Liver-D14) without seeding
factor correction is shown for wild-
type (6–7) and Ikaros DN2/2 em-
bryos (4).1208 Regulation of HSCs by Ikaros
wild-type values (Fig. 6 A). In contrast, the absolute num-
ber of mature erythroid-restricted clonogenic precursors
(CFU-E) was reduced to 30% of wild-type levels (Fig. 6 A).
Furthermore, the most immature erythroid-restricted pre-
cursors (BFU-E) were reduced to 5% of wild-type numbers.
In the spleens of Ikaros null mice, all CFC classes, including
CFU-E, BFU-E, CFC-G/M, and CFC-multi, were reduced
in absolute number (Fig. 6 A). However, the frequencies of
all CFCs, with the exception of BFU-E, were higher than
in wild type (Fig. 6 B) due to the observed decrease in
spleen (and BM) cellularity in Ikaros mutants.
A more severe reduction in the absolute number of all
CFCs was detected in Ikaros DN2/2 mice. BFU-E cells
were the most drastically affected in BM and spleen, with
absolute numbers ,1% of wild type (Fig. 6 A). CFU-E
cells were also reduced, but to a lesser extent than BFU-E.
A CFU-E reduction to 5% of wild type was noted in the
BM and to 25% of wild type in the spleen. In the BM, the
absolute number of CFC-G/M cells was reduced to 15% of
wild-type levels, reflecting the reduction in BM cellularity.
Thus, the CFC-G/M frequency was similar to that of
wild-type BM. However, in the Ikaros DN2/2 spleen,
CFC-G/M numbers were greatly increased (greater than
twofold), indicating a dramatic increase in granulomono-
cytic precursors in this normally lymphoid organ (Fig. 6 A).
Nonetheless, no increase in splenic erythroid precursors
(BFU-E and CFU-E) was detected, suggesting specific ef-
fects of the Ikaros mutation on the expansion of myeloid
versus erythroid precursors (see Fig. 8).
Given the BM hypoplasia and abnormal splenic hemo-
poiesis manifested in both Ikaros mutants, the combined to-
tal BM and spleen content of hemopoietic precursors was
calculated per mouse (Fig. 6 C). BFU-E cells are reduced
10-fold in the Ikaros null and 30-fold in Ikaros DN2/2 mice
(Fig. 6 C). These BFU-E reductions are in line with the
reductions seen in the most primitive HSC population.
However, the total number of the later erythroid precur-
sors (CFU-E) was reduced only three- and sixfold in Ikaros
null and DN2/2 mice, respectively. Furthermore, in both
Ikaros mutants, CFC-G/M cells were reduced to 40–75%
of wild-type levels, a less severe decrease than that observed
for other CFC classes.
Although the numbers of myeloid precursors in the
spleens of the Ikaros null and DN2/2 mice (with the excep-
tion of CFC-G/M) are decreased, the number of termi-
nally differentiated erythroid (TER-1191) and myelomono-
cytic (Mac-11/Gr-11) cells is increased in this organ (10,
11). This suggests that the splenic microenvironment is
conducive to the rapid differentiation of myeloid precur-
sors to their mature progeny.
Lack of BM Cells with the Lin2c-kit1Sca-11 Stem Cell Pheno-
type in Ikaros DN2/2 Mice. Hemopoietic cells that lack ex-
pression of mature lineage markers (lin2) and that coexpress
Sca-1/Ly6A and the tyrosine kinase receptor c-kit on their
cell surfaces (lin2c-kit1Sca-11) are highly enriched in HSC
activity in normal mice (27, 28). The HSC-enriched lin2
c-kit1Sca-11 population was detected in Ikaros null BM
(Fig. 7 A, center). In sharp contrast, no c-kit1/Sca-11 cells
were present among the lin2 BM cells of Ikaros DN2/2
mice (Fig. 7 A, right). The lack of BM cells with a lin2
c-kit1Sca-11 surface phenotype in Ikaros DN2/2 mice is
consistent with the dramatic depletion in HSC activity in
these mutant mice.
Analysis of lin2 BM cells from Ikaros null and DN mice
revealed a progressive decrease in the cell surface expres-
sion level of c-kit (Fig. 7 B). Given the importance of the
steel factor/c-kit signaling pathway in the expansion and
differentiation of hemopoietic progenitors (29), we predict
that the decreased expression of c-kit in Ikaros mutant hemo-
poietic cells may underlie some of the progenitor defects.
Molecular Analysis of Ikaros Mutant Hemopoietic Progenitors.
To address the molecular basis of the hemolymphoid defi-
ciencies in Ikaros mutant mice, we analyzed expression of
growth factor receptors, signaling molecules, and transcrip-
tion factors known to be important in the production,
maintenance, and differentiation of hemopoietic cells.
Figure 6. Dynamics in myeloid differentiation in Ikaros mutant mice.
(A) Proportion of absolute CFCs recovered from BM and spleens (Sp) of
Ikaros null and DN2/2 mutants relative to wild type (dashed line) is
shown. The data represent the average 6SEM from a total of eight ani-
mals per genotype. Precursor classes are defined in Materials and Meth-
ods. (B) Frequency of CFCs (i.e., number per 105 cells) in Ikaros null and
Ikaros DN2/2 BM and spleens is shown. Data are standardized to wild-
type frequencies, represented by the dashed line. (C) The combined CFC
content of BM and spleen relative to wild type is shown. CFC content
for the entire bodily BM compartment is included in the calculation by
assuming that one femur represents 10% of total BM.1209 Nichogiannopoulou et al.
Lin2 BM cells from Ikaros null and wild-type mice were
sorted into c-kithi, c-kitlo, and c-kithiSca-11 populations,
and those from Ikaros DN2/2 mice were sorted into c-kithi
and c-kitlo populations and subsequently used for reverse
transcriptase (RT)-PCR analysis (Fig. 7 C). mRNA ex-
pression of the tyrosine kinase receptor flk-2, shown to be
required for HSC differentiation along the B cell lineage
(30), was undetectable in all lin2 BM populations, includ-
ing those that are highly enriched for HSC activity, in
Ikaros null mice (Fig. 7 C, flk-2). Expression of a second re-
lated tyrosine kinase receptor, flk-1, required for develop-
ment of the vascular endothelium from the hemangioblast,
was also tested (31). Flk-1 was expressed in the Ikaros mu-
tant lin2 populations but at a somewhat reduced level com-
pared with wild type (Fig. 7 C, Flk1). The mRNA level of
the tyrosine phosphatase Shp-1, a downstream effector of
the c-kit signaling pathway, was also determined and found
not to be significantly different between Ikaros mutant and
wild-type populations (Fig. 7 C, Shp1).
Expression of several transcription factors known to play
key roles in the development of the hemopoietic system
was also determined. Ikaros mutant lin2 cells were analyzed
for the presence of SCL, GATA-1, GATA-2, GATA-3,
and PU.1 transcripts. A small decrease in SCL levels was
seen in the Ikaros null c-kithi and c-kithiSca-11 population
(Fig. 7 C, Scl). Small changes in GATA-2 but not GATA-1
levels were also seen among the Ikaros null and DN2/2
hemopoietic populations, the most dramatic being an in-
crease in GATA-2 levels in the c-kitlo cells in the Ikaros
DN2/2 BM. These possibly reflect changes in hemopoietic
progenitor composition in the lin2 compartment. GATA-3
is expressed among the lin2 hemopoietic cells, possibly
in progenitors undergoing specification along the T cell
lineage. GATA-3 was expressed within lin2 progenitor
populations of Ikaros null mice, which generate T cell pre-
cursors. However, it was not detected in Ikaros DN2/2lin2
populations lacking T cell differentiation potential, reflect-
ing either lack of the relevant precursor population or lack
of expression of the GATA-3 factor in these cells. Finally,
levels of PU.1 are reduced in the c-kithi population of the
Ikaros null mutants but elevated in the same population in
Ikaros DN2/2 BM. The Ikaros mutant lin2 hemopoietic
populations were also analyzed for expression of mRNAs
encoding hemopoietic growth factors and receptors. In the
c-kitlo of Ikaros null and in the c-kitlo-med populations of
Ikaros DN2/2 BM, levels of GM-CSF receptor were signif-
icantly elevated relative to wild type, which could be the
cause or effect of the increase in GM precursors observed
in clonogenic assays.
Discussion
We have previously shown that Ikaros is an essential reg-
ulator of lymphoid lineage specification in the fetal and
adult hemopoietic system. Ikaros is, however, expressed early
during ontogeny of the hemopoietic system and is detected
at high levels in mesodermal progenitors in the splachno-
pleura of the day 8 embryo and within the blood islands of
the YS (reference 18 and Georgopoulos, K., unpublished
results). In addition, in adult hemopoietic sites, Ikaros is ex-
pressed within cell populations that are highly enriched in
HSCs (15, 32). A detailed analysis of the entire hemopoie-
tic hierarchy in Ikaros mutant mice is presented here, re-
vealing a role for Ikaros in the production or activity of the
self-renewing HSC. These studies also provide evidence
for a functional interplay between Ikaros and other nuclear
factors, including family members during differentiation of
the most primitive of hemopoietic progenitors.
Mice homozygous for an Ikaros null or DN mutation
show a decrease in BM cellularity that cannot be ascribed
solely to the lack of B cell differentiation. In addition, an
Figure 7. Analysis of lin2 Ikaros mutant hemopoietic cells. (A) Total
BM cells from 2–4 wk-old wild-type (1/1), Ikaros null (Ik 2/2), and
Ikaros (Ik) DN2/2 mice were lineage depleted and stained for c-kit
and Sca-1 (as described in Materials and Methods). The c-kithi, c-kitlo,
and c-kit1Sca-11 populations are boxed and percentages are indicated. (B)
Histograms of cell surface c-kit expression in Ikaros mutant lin2 BM pop-
ulations (dashed lines) and wild type (solid lines) are shown. The left and
right panels contrast Ikaros null and Ikaros DN2/2 cells, respectively, with
wild-type cells. (C) RT-PCR analysis of sorted hemopoietic cells from
wild-type and Ikaros mutant mice. BM cells were lineage depleted and
sorted according to expression of c-kit and Sca-1, as indicated in A.
cDNA was obtained from each sorted population and PCR amplified for
the indicated genes. cDNA levels were normalized to HPRT levels.1210 Regulation of HSCs by Ikaros
increase in erythromyeloid precursors is detected in the
spleens of Ikaros mutant mice, an observation not made in
other strains of mice depleted of lymphocytes. The pro-
gressive development of anemia in mice homozygous for
the Ikaros DN2/2 mutation, manifested as a progressive drop
in hematocrit, is also indicative of a failure of the hemopoi-
etic system to supply mature erythrocytes at normal levels.
BM progenitors from Ikaros null mice provide short- and
long-term contribution to most of the hemopoietic lin-
eages, apart from the lymphoid, when transferred alone
into lethally irradiated recipients. However, when measured
against wild-type BM in a competitive assay, a severe de-
pletion in both short- and long-term repopulating activities
is revealed. Ikaros null BM is unable to contribute to any
hemopoietic lineages when competed against wild-type
congenic BM at a ratio below 10:1. Even when present in
a .10-fold excess, only limited hemopoietic contribution
is observed from Ikaros null BM, suggesting a reduced
number of HSCs in these mutants. In contrast, wild-type
BM, when used at an excess of 10:1 over competitor, re-
populates 100% of all hemopoietic lineages tested. Thus,
there is a quantitative reduction estimated to be 30–40-fold
in the number of HSCs in Ikaros null mice (Fig. 8).
A greater reduction in HSC numbers is detected in mice
homozygous for a DN Ikaros mutation. Ikaros DN2/2 BM
is unable to provide LTR in a competitive assay, even when
used at 100-fold excess to wild-type congenic BM, indicat-
ing a severe depletion in stem cell activity below assayable
levels. A limited short-term hemopoietic contribution from
the Ikaros DN2/2 BM was detected in both competitive
and radioprotective assays, suggesting a transient expansion
in short-term repopulating cells. Wild-type BM cells sorted
according to the absence of cell surface lineage-specific
markers and expression of c-kit and Sca-1/Ly6A are en-
riched for HSC activity (28). This population of cells was
absent from the BM of Ikaros DN2/2 mice, consistent with
the depletion in both short- and long-term repopulating
activity in these mutants.
The defect in hemopoietic progenitors within Ikaros mu-
tants was also illustrated by the ability of wild-type BM to
provide hemopoietic reconstitution to these animals without
their prior conditioning. Transplant of wild-type BM cells
into unirradiated Ikaros null mice resulted in chimeric animals
in which some hemopoietic lineages, such as T, Mac-11, and
Gr-1lo cells, all of which are unaffected by the Ikaros muta-
tion, derive from both wild-type and Ikaros mutant precur-
sors. B lineage cells and Gr-1hi cells, neither of which are pro-
duced from Ikaros mutant progenitors, are derived exclusively
from wild-type precursors. In Ikaros DN2/2 mutants, repop-
ulation by wild-type BM without the need for prior condi-
tioning is observed for all lineages. The ability of normal BM
to function in Ikaros mutants suggests that the Ikaros defects
are manifest within hemopoietic populations rather than in
nonhemopoietic accessory cells of the BM and spleen.
Figure 8. Effects of Ikaros deficiency on the hemopoietic progenitor/precursor hierarchy. Commitment of a mesodermal precursor to the HSC fate, self-
renewal (curved arrow), and subsequent progression through intermediate steps that involve long- and short-term repopulating progenitors and precursors
to terminally differentiated progeny is illustrated. The mesodermal precursor commitment step as a possible target for the Ikaros deficiencies and a cause for
the reduction in HSCs is indicated as the perpendicular intersection of two broken lines, which also indicates a possible defect in HSC renewal. Complete
blocks in the differentiation of Ikaros-deficient progenitors toward the B cell and NK lineages are shown as the perpendicular intersection of two solid lines.
The increase in the differentiation output of these mutant precursor populations toward the erythromyeloid lineage is depicted with green arrows.1211 Nichogiannopoulou et al.
Evaluation of the more committed hemopoietic precur-
sor compartment in Ikaros mutant mice reveals amelioration
of their phenotypes. CFU-S14 clonogenic assays were used
as a measure of the multilineage erythromyeloid-restricted
progenitors. An eightfold reduction in CFU-S14 activity
was detected in Ikaros null mice, whereas the reduction in
Ikaros DN2/2 mice was 34-fold. In vitro clonogenic assays
show that BFU-E, the earliest erythroid-restricted precur-
sor, is reduced by 10- and 30-fold in Ikaros null and Ikaros
DN2/2 mice, respectively. This reduction in BFU-E may
in part explain the decrease in CFU-S14, particularly as
wild-type spleen colonies are comprised mainly of erythroid
lineage cells. However, later stage erythroid precursors
(i.e., CFU-E) are not as severely compromised, with only
three- and sixfold reductions detected in Ikaros null and
DN2/2 mice. Lack of Ikaros has an even lesser effect (25
and 50% decrease) on the number of myelomonocytic pre-
cursors, indicating their possible preferential expansion rel-
ative to BFU-E (Fig. 8). The decrease in CFU-S14 and
BFU-E activity in Ikaros mutant mouse strains is smaller
than the estimated 30–100-fold decrease in LTR cells, sug-
gesting the existence of partial compensatory mechanisms
after HSC commitment. Alternatively, Ikaros may normally
function in early hemopoietic progenitors to limit differen-
tiation along the myeloid lineages, a constraint that is re-
moved upon Ikaros inactivation (Fig. 8).
To determine if the hemopoietic defects manifested in
Ikaros mutants are the result of a defect in the production or
maintenance of HSCs, we examined the hemopoietic pre-
cursor content of embryonic and fetal hemopoietic sites.
CFU-S14 activities were measured in the AGM and the YS
on day 10 and the fetal liver on day 14 of Ikaros DN2/2
embryos. CFU-S14 activity was depleted in all three sites in
Ikaros DN2/2 embryos. The effects of Ikaros mutation on
fetal hemopoietic precursors closely match those seen post-
natally in the BM and spleen. Depletion of fetal precursors
in the Ikaros mutant embryos supports the idea that Ikaros
regulates the production of hemopoietic progenitors during
ontogeny of the hemopoietic system.
Molecular analysis of lin2 hemopoietic populations in
Ikaros mutant mice revealed a severe reduction in expres-
sion of two tyrosine kinase receptors important for HSC
development. Surface expression of c-kit is progressively
reduced from Ikaros null to Ikaros DN2/2 hemopoietic
cells, and mRNA expression of flk-2 is missing in both
mutant populations. Flk-2 was originally identified as a ty-
rosine kinase receptor expressed in fetal liver populations
enriched for HSCs (33). It has previously been reported
that flk-2 null BM has reduced competitive repopulation
activity against wild-type BM, suggesting a potential deple-
tion in HSCs (30). In addition, the number of B cell pre-
cursors in the flk-2 null mice is reduced. Both flk-2 hemopoi-
etic  phenotypes correlate with those observed in Ikaros
mutants. However, hemopoietic progenitors in Ikaros mu-
tant mice appear to be more severely reduced in number,
and B cell precursors are absent. It is possible that lack of
the flk-2 tyrosine kinase receptor, compounded with a re-
duction in levels of cell surface c-kit, and possibly other
unidentified factors, which are also required at the early
stages of B, T, and HSC differentiation, may account for the
more severe HSC and B cell phenotypes manifested in Ikaros
mutant mice. Indeed, flk-2 and c-kit double mutants display
a far more severe hemopoietic phenotype than that manifested
by either mutations alone, resulting in early lethality (30). It
is also significant that the difference in c-kit expression be-
tween Ikaros null and DN2/2 progenitors directly correlates
with the severity in HSC defect manifested in these mutant
mice. Expression of the T cell–determining transcription
factor, GATA-3, is missing from the Ikaros DN2/2 mice
but is present among the Ikaros null lin2 hemopoietic pop-
ulations. GATA-3 expression, or lack thereof, correlates with
the T cell differentiation potential of Ikaros mutants. Inter-
ference from the Ikaros DN isoforms toward the activity of
other Ikaros-interacting factors expressed in the early hemo-
poietic progenitor compartment may impair GATA-3 ex-
pression in these cells and block their T cell differentiation
potential. Finally, increase in expression of the myeloid-
specific GM-CSF receptor within Ikaros mutant early hemo-
poietic progenitors may underlie the apparent expansion of
the myeloid precursors and their progeny despite the dra-
matic reduction in hemopoietic progenitor numbers.
The progressive depletion in long- and short-term hemo-
poietic progenitors and T cell precursors from the Ikaros null
to DN2/2 mice supports a role for Ikaros and its interacting
factors (21) in the development and differentiation of HSCs.
Ikaros proteins are all engaged in a higher order complex
with family members and components of two distinct chro-
matin remodeling complexes (21). The proper nuclear com-
partmentalization and gene targeting of these chromatin re-
modeling complexes manifested in the presence of Ikaros
and its family members are likely to be as critical for differen-
tiation and homeostasis of the hemopoietic system as the
Ikaros protein itself. The progressive depletion in long- and
short-term hemopoietic progenitors and T cell precursors
from the Ikaros null to DN2/2 mice may reflect progressive
mistargeting of these remodeling complexes in the nuclei of
HSCs in the absence of Ikaros and through DN interference
with the activity of its family members, the expression of
which is not affected by the Ikaros mutations (data not shown).
Ikaros remodeling complexes may control hemopoietic
lineage commitment decisions by potentiating expression
of genes that include at least the tyrosine kinase receptors
flk-2 and c-kit and possibly the transcription factor GATA-3,
required for differentiation along the B and T cell lineages.
We have recently shown that Ikaros proteins provide T cell
activation thresholds (34), possibly by regulating changes in
chromatin structure (21). Ikaros may thus control HSC ac-
tivation by providing thresholds to signaling pathways for
c-kit and other receptors. In the absence of Ikaros, the sig-
naling thresholds for these pathways may be lowered, al-
lowing HSCs and their progeny to enter the cell cycle more
readily and possibly deplete the most primitive quiescent
stem cell pool. Further studies on the cycling status of Ikaros
mutant HSC and the effects of cell cycle–promoting factors
on the hemopoietic compartment of Ikaros mutant mice
will address this central question of self-renewal.1212 Regulation of HSCs by Ikaros
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